545 related articles for article (PubMed ID: 21377916)
1. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer.
Neurath MF; Finotto S
Cytokine Growth Factor Rev; 2011 Apr; 22(2):83-9. PubMed ID: 21377916
[TBL] [Abstract][Full Text] [Related]
2. Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells.
Finotto S; Eigenbrod T; Karwot R; Boross I; Doganci A; Ito H; Nishimoto N; Yoshizaki K; Kishimoto T; Rose-John S; Galle PR; Neurath MF
Int Immunol; 2007 Jun; 19(6):685-93. PubMed ID: 17496315
[TBL] [Abstract][Full Text] [Related]
3. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.
Atreya R; Mudter J; Finotto S; Müllberg J; Jostock T; Wirtz S; Schütz M; Bartsch B; Holtmann M; Becker C; Strand D; Czaja J; Schlaak JF; Lehr HA; Autschbach F; Schürmann G; Nishimoto N; Yoshizaki K; Ito H; Kishimoto T; Galle PR; Rose-John S; Neurath MF
Nat Med; 2000 May; 6(5):583-8. PubMed ID: 10802717
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 trans-signalling in chronic inflammation and cancer.
Scheller J; Ohnesorge N; Rose-John S
Scand J Immunol; 2006 May; 63(5):321-9. PubMed ID: 16640655
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
Rose-John S; Scheller J; Elson G; Jones SA
J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
[TBL] [Abstract][Full Text] [Related]
6. IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state.
Nishihara M; Ogura H; Ueda N; Tsuruoka M; Kitabayashi C; Tsuji F; Aono H; Ishihara K; Huseby E; Betz UA; Murakami M; Hirano T
Int Immunol; 2007 Jun; 19(6):695-702. PubMed ID: 17493959
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
Fujimoto M; Serada S; Mihara M; Uchiyama Y; Yoshida H; Koike N; Ohsugi Y; Nishikawa T; Ripley B; Kimura A; Kishimoto T; Naka T
Arthritis Rheum; 2008 Dec; 58(12):3710-9. PubMed ID: 19035481
[TBL] [Abstract][Full Text] [Related]
8. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model.
Matsumoto S; Hara T; Mitsuyama K; Yamamoto M; Tsuruta O; Sata M; Scheller J; Rose-John S; Kado S; Takada T
J Immunol; 2010 Feb; 184(3):1543-51. PubMed ID: 20042582
[TBL] [Abstract][Full Text] [Related]
9. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
10. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer.
Chalaris A; Garbers C; Rabe B; Rose-John S; Scheller J
Eur J Cell Biol; 2011; 90(6-7):484-94. PubMed ID: 21145125
[TBL] [Abstract][Full Text] [Related]
11. IL-21 and IL-21R are not required for development of Th17 cells and autoimmunity in vivo.
Sonderegger I; Kisielow J; Meier R; King C; Kopf M
Eur J Immunol; 2008 Jul; 38(7):1833-8. PubMed ID: 18546146
[TBL] [Abstract][Full Text] [Related]
12. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.
Hohki S; Ohguro N; Haruta H; Nakai K; Terabe F; Serada S; Fujimoto M; Nomura S; Kawahata H; Kishimoto T; Naka T
Exp Eye Res; 2010 Aug; 91(2):162-70. PubMed ID: 20420831
[TBL] [Abstract][Full Text] [Related]
13. IL-6: regulator of Treg/Th17 balance.
Kimura A; Kishimoto T
Eur J Immunol; 2010 Jul; 40(7):1830-5. PubMed ID: 20583029
[TBL] [Abstract][Full Text] [Related]
14. Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity.
Lissilaa R; Buatois V; Magistrelli G; Williams AS; Jones GW; Herren S; Shang L; Malinge P; Guilhot F; Chatel L; Hatterer E; Jones SA; Kosco-Vilbois MH; Ferlin WG
J Immunol; 2010 Nov; 185(9):5512-21. PubMed ID: 20870936
[TBL] [Abstract][Full Text] [Related]
15. Protein kinase B/Akt signals impair Th17 differentiation and support natural regulatory T cell function and induced regulatory T cell formation.
Pierau M; Engelmann S; Reinhold D; Lapp T; Schraven B; Bommhardt UH
J Immunol; 2009 Nov; 183(10):6124-34. PubMed ID: 19841181
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 trans-signaling in inflammatory bowel disease.
Mitsuyama K; Sata M; Rose-John S
Cytokine Growth Factor Rev; 2006 Dec; 17(6):451-61. PubMed ID: 17045835
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune inflammation from the Th17 perspective.
Furuzawa-Carballeda J; Vargas-Rojas MI; Cabral AR
Autoimmun Rev; 2007 Jan; 6(3):169-75. PubMed ID: 17289553
[TBL] [Abstract][Full Text] [Related]
18. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
[TBL] [Abstract][Full Text] [Related]
19. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells.
Fitzgerald DC; Zhang GX; El-Behi M; Fonseca-Kelly Z; Li H; Yu S; Saris CJ; Gran B; Ciric B; Rostami A
Nat Immunol; 2007 Dec; 8(12):1372-9. PubMed ID: 17994023
[TBL] [Abstract][Full Text] [Related]
20. IL-22 and inflammation: leukin' through a glass onion.
Zenewicz LA; Flavell RA
Eur J Immunol; 2008 Dec; 38(12):3265-8. PubMed ID: 19016525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
